1. S100A8-mediated metabolic adaptation controls HIV-1 persistence in macrophages in vivo.
- Author
-
Real F, Zhu A, Huang B, Belmellat A, Sennepin A, Vogl T, Ransy C, Revol M, Arrigucci R, Lombès A, Roth J, Gennaro ML, Bouillaud F, Cristofari S, and Bomsel M
- Subjects
- Alarmins, Anti-Retroviral Agents therapeutic use, CD4-Positive T-Lymphocytes, Calgranulin A, Humans, Macrophages, Matrix Metalloproteinase 7 pharmacology, Matrix Metalloproteinase 7 therapeutic use, Virus Latency, Virus Replication, HIV Infections drug therapy, HIV-1 physiology
- Abstract
HIV-1 eradication is hindered by viral persistence in cell reservoirs, established not only in circulatory CD4
+ T-cells but also in tissue-resident macrophages. The nature of macrophage reservoirs and mechanisms of persistence despite combined anti-retroviral therapy (cART) remain unclear. Using genital mucosa from cART-suppressed HIV-1-infected individuals, we evaluated the implication of macrophage immunometabolic pathways in HIV-1 persistence. We demonstrate that ex vivo, macrophage tissue reservoirs contain transcriptionally active HIV-1 and viral particles accumulated in virus-containing compartments, and harbor an inflammatory IL-1R+ S100A8+ MMP7+ M4-phenotype prone to glycolysis. Reactivation of infectious virus production and release from these reservoirs in vitro are induced by the alarmin S100A8, an endogenous factor produced by M4-macrophages and implicated in "sterile" inflammation. This process metabolically depends on glycolysis. Altogether, inflammatory M4-macrophages form a major tissue reservoir of replication-competent HIV-1, which reactivate viral production upon autocrine/paracrine S100A8-mediated glycolytic stimulation. This HIV-1 persistence pathway needs to be targeted in future HIV eradication strategies., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF